Teriparatide vs Palifermin
Head-to-head comparison of Teriparatide (Parathyroid Hormone (1-34)) and Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Teriparatide | Palifermin |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Parathyroid Hormone (1-34) | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) |
| Molecular Weight | 4117 Da | 16.3 kDa |
| Half-Life | about 1 hour | 4–6 hours |
| Amino Acids | 34 | 140 |
| Typical Dose | 20 mcg daily | 60 µg/kg/day |
| Route | Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 250 |
| Research Status | Clinical | Clinical |
Teriparatide Benefits
- ✓stimulates bone formation
- ✓supports fracture union
- ✓improves bone mineral density
- ✓may aid bone remodeling
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
Teriparatide Dosing
20 mcg subcutaneous daily|intermittent anabolic exposure|monitor calcium and vitamin D status
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
Teriparatide Side Effects
- ⚠hypercalcemia
- ⚠nausea
- ⚠dizziness
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Research Overview
Teriparatide
Teriparatide has extensive clinical literature showing anabolic effects on bone and investigational use in delayed unions and nonunions. It is one of the best-studied peptide-based options for skeletal recovery.
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.